Steady as she goes...Soft Tissue Fixation Market on track to achieve SmartTRAK estimates for FY 2019

For the third quarter of 2019, the WW Soft Tissue Fixation Market revenue was up +3.4% YoY. Aggregate growth for the quarter benefited from solid revenue growth in the Hip Labral Repair segment, which was up +10.1% YoY, based on SmartTRAK Financial Dashboard. 

Focusing on the US region, the Soft Tissue Fixation market was up YoY. However, on a sequential basis, growth was slightly down, attributable to the seasonal nature of Sports Medicine where many surgeries are elective with Q4 generally seeing high procedure volumes. Aggregate growth for Q319 was pulled by notable growths in the Shoulder Soft Tissue Fixation and the Hip Labral Repair segments. Although Knee Soft Tissue Fixation represents the 2nd largest segment, revenue growth was marginal, with the moderate growth seen steady at slightly above  ...

Among the many topics covered in the complete, comprehensive Q319 Soft Tissue Fixation Market Recap*, including all the news, financial data, revenues, charts and SmartTRAK's expert analysis, are:

Single-injection holding the torch in a market essentially flat, impacted by ferocious pricing pressures and declines in multi-injections

For the third quarter of 2019, the US Joint Fluid market revenue was essentially flat, +0.2% vs Q318. Aggregate growth for the quarter was pulled into slightly positive territory by a solid revenue growth of 14.3% YoY in single injection, according to the recently published SmartTRAK Financial Dashboard. However, strength in that segment was barely enough to counter revenue declines in 3- and 5-injections, while the 2-injection segment is still not large enough to make a significant contribution to the overall recovery of the US Joint Fluid market.

The single-injection segment held on to the market lead for Q319. Despite pricing pressure between competitors in this segment, revenue growth further solidifies the trend that the HA market is moving to the lowest treatment cycle.  For Q319, 3-injection products dropped down, strained by heavy competition and a persistent price war. Trailing behind is the 5-injections with...

Among the many topics covered in the comprehensive Q319 US Joint Fluid Market Recap* are:

SmartTRAK's Senior Regenerative Medicine Analyst, Freddy Buntoum, attended TOBI 2019 this summer. Here's a look at some of the key trends and takeaways in Orthobiologics from the 10th PRP & Regenerative Medicine Symposium, hosted by TOBI, that are still prevalent today.

Q219 saw marginal revenue growth amid single-injection momentum and competitive pricing pressure

The numbers are in and now that we are in the second quarter of 2019, the US Joint Fluid market seems to be getting off its slow-ish start of the year, gaining some momentum with the single-injection segment pushing the aggregate total revenue into positive growth, according to the recently published SmartTRAK Financial Dashboard. This, despite relentless and fierce pricing competition in the multi-injection arena. 

Among the many topics covered in the Q219 US Joint Fluid Market Recap* are:

OrthogenRx CEO & Founder Michael Daley talks about the Company’s new 3-injection HA product, TriVisc and what will come next.

Michael Daley, CEO & Founder of OrthogenRx, a US medical device company focused on treatments for musculoskeletal conditions, talked about TriVisc, the Company’s new 3-injection hyaluronic acid (HA) product for knee osteoarthritis, as well as the future at OrthogenRx, in an interview with SmartTRAK at the American Academy of Orthopaedic Surgeons 2019 Annual Meeting held March 12-14, 2019 in Las Vegas, NV.

What is the rational for OrthogenRx to bring TriVisc now to a very crowded 3-injection HA segment?

To have a presence in the entire US HA market, OrthogenRx aims to provide...

Revenues down again, competitive pricing pressures remain, market is under FDA scrutiny

After a sluggish start of the year, the US Joint Fluid market gained steam during the quarter as demand and volumes picked up in several market segments in spite of intense competitive pricing pressures. Revenues were within SmartTRAK’s projected range with a marginal decline of -0.3% YoY according to the recently published SmartTRAK Financial Dashboard.

For Q119, the 3-injection segment accounted for 44.6%  of the US Joint Fluid market, followed by single-injection products at 41.5%, the 5-injection segment at 12.9% and rounding up the market with the 2-injection segment at 1.1%, according to SmartTRAK Financial Dashboard results. The single-injection segment showed good recovery from last year driven by increased adoption of newer products and/or sales expansion measures by some suppliers. The 3-injection segment was down in the low single digits during Q119 owing to continued and fierce pricing competition. The 5-injection segment showed no reprieve from its downward trend, declining...

Among the many topics covered in the Q119 US Joint Fluid Market Recap are:

Revenues down again, owing to intense competitive pricing pressures

Pricing pressure continued to negatively impact the US Joint Fluid market, which experienced a decline of -7.9% based on Q418 revenues according to SmartTRAK Financial Dashboard. While this market continued to see unit volume increases, ASPs experienced notable declines over the past four quarters as a result of several companies not listing ASPs to CMS, which fueled competitive pricing. Additionally, revenues were impacted by the Anthem non-coverage decision that took effect in Q118 and kept impacting suppliers over the course of the year...

Among the many topics covered in the Q418/FY18 Joint Fluid Market Recap: